Michael Kiernan to Double-Blind Method
This is a "connection" page, showing publications Michael Kiernan has written about Double-Blind Method.
Connection Strength
0.203
-
Kiernan MS, Wentworth D, Francis G, Martinez FA, Dickstein K, Komajda M, Zannad F, Neaton JD, Konstam MA. Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. Eur J Heart Fail. 2012 Dec; 14(12):1401-9.
Score: 0.087
-
Natov PS, Ivey-Miranda JB, Cox ZL, Rao VS, Butler J, Konstam MA, Kiernan MS, Kapur NK, Testani JM. Increased Spironolactone Dosing in Acute Heart Failure Alters Potassium Homeostasis but Does not Enhance Decongestion. J Card Fail. 2024 Nov; 30(11):1522-1526.
Score: 0.048
-
Mann DL, Givertz MM, Vader JM, Starling RC, Shah P, McNulty SE, Anstrom KJ, Margulies KB, Kiernan MS, Mahr C, Gupta D, Redfield MM, Lala A, Lewis GD, DeVore AD, Desvigne-Nickens P, Hernandez AF, Braunwald E. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA Cardiol. 2022 01 01; 7(1):17-25.
Score: 0.041
-
Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2016 Aug 02; 316(5):500-8.
Score: 0.028